279 Results for "

Dual targeting

" in MedChemExpress (MCE) Product Catalog:
Products (279)

279 Results for "Dual targeting" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-P99714
CAS No.: 2416595-46-3
Synonyms: MGD019

Target:  

PD-1/PD-L1 CTLA-4

Research Areas:  

Cancer

Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
loading...
    loading...
Cat. No.: HY-W075603
CAS No.: 1031443-55-6
Synonyms: 2,6-Diiodo-Pyrromethene 546
2,6-Diiodo-BODIPY 493/503 (2,6-Diiodo-Pyrromethene 546) is a 2,6-diiodo-substituted BODIPY intermediate that can be used to synthesize dual-organelle-targeted BODIPY-cyanostilbene fluorophores. 2,6-Diiodo-BODIPY 493/503 is applicable to research related to fluorescent dye synthesis .
loading...
    loading...
Cat. No.: HY-P99674
CAS No.: 2364496-42-2
Synonyms: GEN-3009

Research Areas:  

Cancer

Ivicentamab (GEN-3009) is a bispecific antibody targeting CD37 with dual epitopes. Ivicentamab carries an E430G mutation in the Fc region, which efficiently promotes IgG hexamer formation on the surface of target cells. Ivicentamab provides the parental variable regions for an H429F-engineered anti-CD37 bispecific antibody, enabling it to exert complement-dependent cytotoxicity in Daudi lymphoma cells. Ivicentamab is mainly used in lymphoma-related research .
loading...
    loading...
Cat. No.: HY-172429A
Synonyms: ORIC-114 hemihydrate
Target:  

EGFR

Research Areas:  

Neurological Disease Cancer

Enozertinib (ORIC-114) hemihydrate is an orally active, CNS-penetrant, highly selective and irreversible dual EGFR/HER2 inhibitor that exhibits potent and targeted inhibition of exon 20 insertion mutations. Enozertinib hemihydrate exhibits high kinome selectivity for the EGFR family of receptors to reduce off-target kinase liabilities. Enozertinib hemihydrate induces tumor regression and demonstrates antitumor activity in central nervous system and non-small cell lung cancer (NSCLC) tumor models. Enozertinib hemihydrate can be used for the research of solid tumors and NSCLC .
loading...
    loading...
Cat. No.: HY-147253
CAS No.: 2409088-11-3
Synonyms: NS 089; NCNP 02
Target:  

DNA/RNA Synthesis

Research Areas:  

Neurological Disease

Brogidirsen (NS 089; NCNP 02) is a a dual-targeting antisense oligonucleotide. Brogidirsen can induce dystrophin protein experession. Brogidirsen can be used for the research of Duchenne muscular dystrophy .
loading...
    loading...
Cat. No.: HY-164296
CAS No.: 2760408-63-5
Research Areas:  

Cancer

SMP-96745 is a dual-reagent linkage assembly unit that can conjugate with targeting moieties to form dual-reagent targeted linker-drug conjugates, such as ADC. SMP-96745 is applicable to the research of breast adenocarcinoma and gastric cancer .
loading...
    loading...
Cat. No.: HY-126320
CAS No.: 2407957-87-1
Purity:  98.01%
Target:  

EGFR c-Met/HGFR

Research Areas:  

Cancer

EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC .
loading...
    loading...
Cat. No.: HY-172699A
Target:  

Liposome

Research Areas:  

Cancer

DSPE-PEG3400-ANG is a PEG compound which composed of DSPE and a dual-targeting ligand (Angiopep-2, ANG). ANG exhibits high LRP1 binding efficiency and has been used for glioma-targeting delivery. DSPE-PEG3400-ANG can be used for drug delivery .
loading...
    loading...
Cat. No.: HY-111313
CAS No.: 844645-08-5
Research Areas:  

Metabolic Disease

JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pKis of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease .
loading...
    loading...
Cat. No.: HY-155672
CAS No.: 5972-45-2
Purity:  99.5%
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

JPC0323 is a dual 5-HT2C/5-HT2A receptor positive allosteric modulator. JPC0323 has on-target properties, acceptable plasma exposure and brain penetration. JPC0323 can be used for the research of neurological disease .
loading...
    loading...
Cat. No.: HY-P10978
CAS No.: 3137461-57-2
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide (68Ga and 18F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC50 value of 2.45 nM. NK224 visualizes tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-176287
ARN25657 is a dual-acting D3R/GSK-3β modulator. ARN25657 has both partial D3R agonist activity (EC50 = 15.2 nM, Ki =1.5 nM) and potent GSK-3β inhibitor activity (IC50 = 19.3 nM). ARN25657 exhibits excellent GSK-3β selectivity over FYN, PKA, and CDK5/p35. ARN25657 inhibits P-glycoprotein (P-gP)-mediated acetoxymethyl calcein efflux and improves in vitro ADME properties while maintaining a balanced dual-target profile. ARN25657 is useful for studying bipolar disorder and related neuropsychiatric disorders .
loading...
    loading...
Cat. No.: HY-146160
CAS No.: 3032621-10-3
Target:  

PARP HDAC

Research Areas:  

Cancer

PARP-1/HDAC-IN-1 is a PARP-1/HDAC6 dual targeting inhibitor with IC50s of 68.90 nM and 510 nM, respectively. PARP-1/HDAC-IN-1 displays remarkable anticancer, anti-migration and anti-angiogenesis activities .
loading...
    loading...
Cat. No.: HY-162519
Synonyms: LZ90
LZFPN-90 (LZ90) is a dual NAMPT/PD-L1 targeting compound. LZFPN-90 inhibits PD-1/PD-L1 interaction and NAMPT activity. LZFPN-90 inhibits cell growth in a NAMPT-dependent manner and blocks the cell cycle, subsequently inducing apoptosis. LZFPN-90 exerted target-dependent antitumor activities, affecting metabolic processes and the immune system .
loading...
    loading...
Cat. No.: HY-176877
CAS No.: 1198784-83-6
Glucocorticoid receptor/IL-6-IN-2 (Compound 36) is a selective dual inhibitor targeting the glucocorticoid receptor (GR) and IL-6 signaling pathway (IC50 values of 40 nM and 19 nM, respectively). Glucocorticoid receptor/IL-6-IN-2 is promising for research of inflammatory diseases like rheumatoid arthritis and asthma .
loading...
    loading...
Cat. No.: HY-120107
CAS No.: 1799548-33-6
Target:  

Parasite

Research Areas:  

Inflammation/Immunology

OAT-177 is a potent dual inhibitor targeting acidic mammalian chitinase (AMCase) and chitotriosidase (CHIT1) with an IC50=14.2 nM for human AMCase and IC50=232 nM for human CHIT1. OAT-177 is promising for research of chronic inflammatory and fibrotic-related lung diseases such as asthma and idiopathic pulmonary fibrosis .
loading...
    loading...
Cat. No.: HY-175973
Target:  

Cholinesterase (ChE)

Research Areas:  

Neurological Disease

AChE/BChE-IN-30 (Compound 3g) is a Cholinesterase dual-target competitive inhibitor. AChE/BChE-IN-30 can inhibit AChE and BChE with IC50 values of 0.338 and 2.087 μM and Ki values of 0.045 and 0.789 μM. AChE/BChE-IN-30 can be used for the research of neurological disease, such as Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-177134
CAS No.: 2243235-80-3
Target:  

VEGFR c-Met/HGFR

Research Areas:  

Cancer

Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-W037850
CAS No.: 13074-39-0
Synonyms: 2-Aminoadamantane
Target:  

HyT

Research Areas:  

Neurological Disease Cancer

Adamantan-2-amine (2-Aminoadamantane) serves as the hydrophobic tag structural unit of Tubulin degrader 2 (HY-161641) and is used for the synthesis of anticancer drugs that target tubulin via a dual mechanism. Adamantan-2-amine can be applied in research on breast cancer, lung cancer, colorectal cancer, and Parkinson's syndrome .
loading...
    loading...
Cat. No.: HY-160557
CAS No.: 2251709-89-2
Research Areas:  

Cancer

PLK1/BRD4-IN-2 (compound 15) is a BI-2536 (HY-50698) analog and dual inhibitor that targets both Polo-like kinase 1 (PLK1) and BRD4bromodomain (BRD4-BD1 IC50=28 nM, PLK1 IC50=40 nM) .
loading...
    loading...